'Clear Role' for PARP Inhibitors in Advanced Ovarian Cancer

Maurie Markman, MD


April 17, 2018

Hello. I'm Dr Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I want to briefly highlight a new development in the management of ovarian cancer which again emphasizes the importance of PARP inhibitors in this malignancy.

The US Food and Drug Administration recently approved rucaparib as a maintenance strategy in patients with ovarian cancer who responded to a second-line platinum-based chemotherapy regimen. This marks the third PARP inhibitor, joining olaparib and niraparib, approved for treatment in the maintenance setting.

The announcement reinforces what is well recognized now in the oncology community: that this class of agents is active both as a maintenance strategy and as a treatment strategy. A number of ongoing trials are looking to expand the indications. There is a lot of excitement about this approach, particularly about potential expansion of the patient population that might benefit. The indications do not specifically require a biomarker based upon the data for use of this agent in the maintenance setting.

The possibility of combining PARP inhibitors with antiangiogenic agents or checkpoint inhibitors for the management of ovarian cancer[1] is clearly very exciting. Those trials are in progress and we all wait for results with great interest.

Again, I want to emphasize this very important development and the clear role that PARP inhibitors have in the management of patients with advanced ovarian cancer. Thank you for your attention.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.